



**Recipient Information**

**1. Recipient Name**

City of Columbus  
240 Parsons Ave  
Clinical Division  
Columbus, OH 43215-5331  
--

**2. Congressional District of Recipient**

03

**3. Payment System Identifier (ID)**

1316400223A1

**4. Employer Identification Number (EIN)**

316400223

**5. Data Universal Numbering System (DUNS)**

932901762

**6. Recipient's Unique Entity Identifier**

**7. Project Director or Principal Investigator**

Ms. Audrey S Regan  
Principle Investigator  
asregan@columbus.gov  
614-645-6790

**8. Authorized Official**

Mrs. Danielle Ohms  
Fiscal Manager  
drohms@columbus.gov  
614-645-0740

**Federal Agency Information**

CDC Office of Financial Resources

**9. Awarding Agency Contact Information**

Ms. Edna Green  
Grants Management Officer  
EGreen@cdc.gov  
770-488-2858

**10. Program Official Contact Information**

Marvin Fleming  
Project Officer  
mqf6@cdc.gov  
404.639.8352

**Federal Award Information**

**11. Award Number**

5 NH25PS005188-03-00

**12. Unique Federal Award Identification Number (FAIN)**

NH25PS005188

**13. Statutory Authority**

This Program is authorized under section 318 of the Public Health Service Act (42 U.S.C. Section 247c, as amended)

**14. Federal Award Project Title**

Central Ohio's Application for the SSuN Program

**15. Assistance Listing Number**

93.977

**16. Assistance Listing Program Title**

Preventive Health Services\_Sexually Transmitted Diseases Control Grants

**17. Award Action Type**

Non-Competing Continuation

**18. Is the Award R&D?**

No

**Summary Federal Award Financial Information**

<b>19. Budget Period Start Date</b>	09/30/2021	<b>- End Date</b>	09/29/2022
<b>20. Total Amount of Federal Funds Obligated by this Action</b>			\$250,000.00
20a. Direct Cost Amount			\$350,000.00
20b. Indirect Cost Amount			\$0.00
<b>21. Authorized Carryover</b>			\$100,000.00
<b>22. Offset</b>			\$0.00
<b>23. Total Amount of Federal Funds Obligated this budget period</b>			\$0.00
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>			\$0.00
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>			\$250,000.00
<b>26. Project Period Start Date</b>	09/30/2019	<b>- End Date</b>	09/29/2024
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>			Not Available

**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

**29. Grants Management Officer - Signature**

Mr. Arthur Lusby  
Grants Management Officer, Team Lead

**30. Remarks**

Non-Competing Continuation: Financial Assistance in the amount of \$250,000



Recipient Information
<b>Recipient Name</b> City of Columbus 240 Parsons Ave Clinical Division Columbus, OH 43215-5331 --
<b>Congressional District of Recipient</b> 03
<b>Payment Account Number and Type</b> 1316400223A1
<b>Employer Identification Number (EIN) Data</b> 316400223
<b>Universal Numbering System (DUNS)</b> 932901762
<b>Recipient's Unique Entity Identifier</b> Not Available
<b>31. Assistance Type</b> Cooperative Agreement
<b>32. Type of Award</b> Other

33. Approved Budget (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$165,243.00
b. Fringe Benefits	\$75,574.00
c. Total Personnel Costs	\$240,817.00
d. Equipment	\$0.00
e. Supplies	\$7,500.00
f. Travel	\$5,860.00
g. Construction	\$0.00
h. Other	\$0.00
i. Contractual	\$95,823.00
<b>j. TOTAL DIRECT COSTS</b>	<b>\$350,000.00</b>
<b>k. INDIRECT COSTS</b>	<b>\$0.00</b>
<b>l. TOTAL APPROVED BUDGET</b>	<b>\$350,000.00</b>
<b>m. Federal Share</b>	<b>\$350,000.00</b>
<b>n. Non-Federal Share</b>	<b>\$0.00</b>

**34. Accounting Classification Codes**

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
0-93906N9	19NH25PS005188	PS	41.51	\$0.00	75-20-0949
1-93906N9	19NH25PS005188	PS	41.51	\$45,455.00	75-21-0949
1-939ZRJQ	19NH25PS005188	PS	41.51	\$36,364.00	75-21-0950
1-939ZRQB	19NH25PS005188	PS	41.51	\$168,181.00	75-21-0950
0-939ZRJQ	19NH25PS005188	PS	41.51	\$0.00	75-20-0950
0-939ZRQB	19NH25PS005188	PS	41.51	\$0.00	75-20-0950



**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 5 NH25PS005188-03-00

FAIN# NH25PS005188

Federal Award Date: 07/21/2021

**Direct Assistance**

<b>BUDGET CATEGORIES</b>	<b>PREVIOUS AMOUNT (A)</b>	<b>AMOUNT THIS ACTION (B)</b>	<b>TOTAL (A + B)</b>
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
<b>Total</b>	<b>\$0.00</b>	<b>\$0.00</b>	<b>\$0.00</b>

# AWARD ATTACHMENTS

City of Columbus

5 NH25PS005188-03-00

---

1. Terms & Conditions

## AWARD INFORMATION

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS19-1907**, entitled “**STD SURVEILLANCE NETWORK (SSuN)**”, and application dated **April 20, 2021**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$250,000** is approved for the Year **03** budget period, which is **September 30, 2021** through **September 29, 2022**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

<b>Strategy A</b>	<b>\$120,000</b>
<b>Strategy B</b>	<b><u>\$130,000</u></b>
<b>Total</b>	<b>\$250,000</b>

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

**This award has been fully funded for budget year 03.**

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

### Technical assistance and capacity building

Existing initial recipient capacity to implement required strategies is assumed for all successful applicants. However, CDC will work with recipients as necessary post-award to identify capacity building and TA needs essential for the overall success of the project. CDC will provide for the use of project funds as appropriate and reasonable for access to training and TA collaboratively identified as essential for successful implementation of SSuN activities.

### Award guidance and monitoring

CDC will support recipients in implementing the requirements of the cooperative agreement, prioritizing activities to produce required outputs and to achieve identified outcomes.

CDC will monitor recipients' performance using multiple approaches (described in the CDC Evaluation and Performance Measurement Strategy section above), such as routine calls,

site visits, emails, standardized reporting of process indicators, recipient feedback and other CDC-generated data reports.

CDC will provide guidance and coordination to recipients to improve data quality and effectiveness of activities, develop specific evaluation strategies, improve data products and build and maintain partnerships.

CDC will provide protocols, data content and structure requirements and explicit expectations for reporting and evaluation.

**Budget Revision Requirement:** By **October 31, 2021** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

**Budget Revision:**

- Provide anticipated start date for all vacant positions
- Under the travel cost category itemize cost and provide names and or title of personnel that will travel
- Under the supplies cost category itemize cost
- Under contractual cost provide 6 elements from budget preparation guidance (Name of Contractor, Method of selection, period of performance, scope of work, method of accountability, itemized budget, and justification)

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

**Addition alternative:** Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

**FUNDING RESTRICTIONS AND LIMITATIONS**

**Notice of Funding Opportunity (NOFO) Restrictions:**

Restrictions that must be considered while planning the programs and writing the budget are:

- Recipients may not use funds for research.

- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
  - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
  - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
- See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<https://www.cdc.gov/grants/additionalrequirements/ar-35.html>).

Recipients may not use funds to purchase HIV Pre-exposure Prophylaxis (PrEP) medications or medications for expedited partner therapy (EPT) for STDs.

Recipients may not use funds to purchase STD medications or to support STD clinical services.

#### **Indirect Costs:**

Indirect costs are not applicable to this award.

### **REPORTING REQUIREMENTS**

**Annual Federal Financial Report (FFR, SF-425):** The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted in the **Payment Management System** no later than 90 days after the end of the budget period. The FFR for this budget period is due by **December 30, 2022**. Reporting timeframe is **September 30, 2021** through **September 29, 2022**. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Additional guidance on submission of Federal Financial Reports can be found at <https://www.cdc.gov/grants/documents/change-in-federal-reporting-fy-2021-recipients.pdf>

**Annual Performance Progress Reporting:** The Annual Performance Progress and Monitoring Report (is due no later than 120 days prior to the end of the budget period, **June 30, 2022**, and serves as the continuation application for the follow-on budget period. This report should include the information specified in the solicitation from the GMS/GMO via [www.grantsolutions.gov](http://www.grantsolutions.gov).

**Performance Progress and Monitoring:** Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, "Performance Progress and Monitoring Report"** (or, **Expiration Date 10/31/2022**). The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Chamarla Brame, Grants Management Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch  
2939 Flowers Rd.  
Mailstop: TV-2  
Fax: N/A  
Email: [cb rame@cdc.gov](mailto:cb rame@cdc.gov) (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)



Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

**Prior Approval:** All requests, which require prior approval, must bear the signature of the authorized organization representative. The recipient must submit these requests by **June 30, 2022**. Additionally, budget and a narrative justification of the request. budget and a narrative justification of the request.

**The following types of requests require prior approval:**

- Lift funding restriction
- Significant redirection of funds (i.e. cumulative changes of 25% of total award)
- Change in scope
- Implement a new activity or enter a sub-award that is not specified in the approved budget
- Apply for supplemental funds
- Change in key personnel
- Extensions to period of performance

**PROGRAM OR FUNDING GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

**PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Subaccount Title: 19NH25PS005188

### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**The GMS contact information is located on page 1, item #9.**

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**The PO contact information is located on page 1, item #10.**

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

**The GMO contact information is located on page 1, item #29.**